AI May Boost Diagnosis of Rare Genetic Disorders
By Lori Solomon HealthDay Reporter
WEDNESDAY, May 1, 2024 -- A random-forest, machine-learning classifier, artificial intelligence-Model organism Aggregated Resources for Rare Variant ExpLoration (AI-MARRVEL), achieves superior accuracy compared with existing methods for genetic diagnosis, according to a study published online in the May issue of NEJM AI.
Dongxue Mao, Ph.D., from the Baylor College of Medicine in Houston, and colleagues evaluated AI-MARRVEL (AIM) using data from patients diagnosed with genetic disorders from three independent cohorts.
The researchers reported that AIM improved the rate of accurate genetic diagnosis, doubling the number of solved cases versus benchmarked methods, across the three real-world cohorts. Using a confidence metric to better identify diagnosable cases from the unsolved pools accumulated over time, AIM achieved a precision rate of 98 percent and identified 57 percent of diagnosable cases out of a collection of 871 cases. After being fine-tuned for targeted settings, including recessive disorders and trio analysis, AIM performance improved. AIM also showed potential for novel disease gene discovery by correctly predicting two newly reported disease genes from the Undiagnosed Diseases Network.
"AIM achieved superior accuracy compared with existing methods for genetic diagnosis," the authors write. "We anticipate that this tool may aid in primary diagnosis, reanalysis of unsolved cases, and the discovery of novel disease genes."
The Baylor College of Medicine and Miraca Holdings Inc. have formed a joint venture with shared ownership and governance of Baylor Genetics, which performs genetic testing and derives revenue.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted May 2024
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.